Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

Leukemia
18:42

Memorial Sloan Kettering Cancer Center

Key Updates in AML, MDS, & MF From ASH

FEATURING Aaron Goldberg
  • 303 views
  • May 2, 2024
  • 4
15:23

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Updates on the Role of SCT in ALL in the Era of CAR-T

FEATURING Jae Park
  • 83 views
  • October 18, 2023
13:15

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Menin Inhibition for KMT2A-Rearranged ALL

FEATURING Eytan Stein
  • 39 views
  • September 29, 2023
30:21

International CML Foundation

ASH 2022 Highlights on CML: Clinical Overview From iCMLf

FEATURING Michael J. Mauro
  • 112 views
  • June 27, 2023
04:55

ASH 2022 Conference Coverage

ASH 2022 Initial Results From SELECT-AML-1: a Phase 2 Study of Tamibarotene + Venetoclax & Azacitidine in RARA+ Newly Diagnosed AML Patients Ineligible for Standard Induction Chemo

FEATURING Eytan Stein
  • 167 views
  • December 16, 2022
04:22

EHA 2022 Conference Coverage

EHA 2022 Tamibarotene in Combination With Ven & Aza in Previously Untreated Adult Pts Selected for RARA+ AML Who Are Ineligible for Standard Induction Therapy (SELECT-AML-1)

FEATURING Eytan Stein
  • 206 views
  • June 21, 2022
  • 2
54:58

PleXus Communications

Expert Perspectives on Treating High-Risk and R/R AML

FEATURING Eytan Stein
  • 141 views
  • June 6, 2022
  • 1
04:36

ecancer

Safety & Efficacy of Asciminib for Heavily Pretreated Patients With CP-CML

FEATURING Michael J. Mauro
  • 26 views
  • April 13, 2022
05:49

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the Safety & Efficacy of Menin Inhibition in MLL-Rearranged and NPM1-Mutant Acute Leukemia: Ph 1 First-in-Human Study of SNDX-5613

FEATURING Eytan Stein
  • 130 views
  • December 23, 2021
  • 1
16:42

University of Miami's 2nd Biennial Miami Leukemia Symposium

IDH Inhibitors in Myeloid Malignancies: What Are the Mechanisms of Resistance in R/R AML? What Are the Strategies to Combine IDH Inhibitors With SoC?

FEATURING Eytan Stein
  • 228 views
  • May 14, 2020
  • 1
06:19

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review of Frontline CLL: Is There a Role for FCR in 2020 and for Which Pts? Does E1912 Suggest Ibrutinib Can Be Considered a Time Limited Therapy?

FEATURING Anthony R. Mato
  • 343 views
  • April 14, 2020
07:59

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review of Frontline CLL: Can We Improve CIT by Adding a Novel Agent to the Backbone? How Can Next Generation BTKis Distinguish Themselves from Ibrutinib?

FEATURING Anthony R. Mato
  • 174 views
  • April 14, 2020
05:08

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Combinations or Sequences of Targeted Agents in CLL: Ibrutinib + Venetoclax for the 1st-Line Treatment - Should MRD Status at EOT Be Driving Treatment Decisions?

FEATURING Anthony R. Mato
  • 78 views
  • April 14, 2020
04:52

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Venetoclax in the R/R CLL: With Additional Follow Up, Is This Regimen Holding up to the Promise of a Time Limited Therapy With Durable Remissions?

FEATURING Anthony R. Mato
  • 27 views
  • April 14, 2020
08:21

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Overcoming BTKi Resistance in CLL: Era of Non-Covalent BTKis? Role of Cellular Therapies

FEATURING Anthony R. Mato
  • 32 views
  • April 14, 2020
15:19

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

29 y/o Male w/ CML: Allograft vs. 3rd Line Therapy - Transplant Is Always Relevant, Ponatinib Raises Concerns in Long-term Use, Asciminib Safe & Active in MDR AML

FEATURING Michael J. Mauro
  • 16 views
  • November 18, 2019
15:59

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

New Kinase Inhibitors for CML: Asciminib, PF-114, & HQP1351

FEATURING Michael J. Mauro
  • 29 views
  • October 16, 2019
27:00

Indy Hematology Review

Acute Myeloid Leukemia - Overview of Available Novel Agents with Unique Mechanisms of Action

FEATURING Martin Tallman
  • 1,783 views
  • June 7, 2019
  • 13
07:46

Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Oral Abstract CML-044: Treatment-Free Remission (TFR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DMR) Discontinuing Dasatinib

FEATURING Michael J. Mauro
  • 16 views
  • November 5, 2018
17:58

Memorial Sloan Kettering Cancer Center

Front-line Strategies in Ph-negative ALL

FEATURING Mark Geyer
  • 172 views
  • July 3, 2018
13:41

Memorial Sloan Kettering Cancer Center

Updates and Challenges in the Management of Chronic Myeloid Leukemia Discussion

FEATURING Michael J. Mauro
  • 146 views
  • May 7, 2018
17:13

Memorial Sloan Kettering Cancer Center

Multi-drug Resistant and Intolerant CML: What to Do?

FEATURING Michael J. Mauro
  • 168 views
  • May 7, 2018
08:42

Memorial Sloan Kettering Cancer Center

IDH Inhibitors in AML

FEATURING Eytan Stein
  • 166 views
  • December 27, 2017